152 results about "Transport protein" patented technology

The invention belongs to the technical field of gene engineering, and particularly relates to a mutant of polymyxin efflux transporter and application of the mutant. The mutant is a PmxD transporter mutant, the amino acid sequence of the PmxD transporter mutant is shown as SEQ ID NO: 1, and compared with wild type PmxD, the polymyxin transport capacity of the PmxD transporter mutant (T38W) is improved by 450.46%; and the total discharge amount of polymyxin is increased by 85.72%. Meanwhile, the mutant can significantly improve the growth ability of the strain on a plate containing 250 [mu] g / mL of polymyxin B, namely significantly improve the autoresistance of paenibacillus polymyxa to polymyxin.

The invention belongs to the technical field of biology, and discloses application of a lignin monomer transporter. The amino acid sequence of the lignin monomer transporter is as shown in SEQ ID No: 1. The application is used for constructing a recombinant strain growing in a culture medium of lignin-derived aromatic compounds, or used for constructing a recombinant strain for producing microbial proteins and / or lipids. According to the novel lignin monomer transport protein driven by deep learning, the metabolic bottleneck of lignin utilization is broken through, the key protein transported by the lignin monomer is excavated, the lignin monomer transport capacity can be endowed to a microbial chassis, and a multifunctional microbial platform is provided for sustainable biological refining.

The invention discloses a cherry sugar transporter gene CpSWEET10 and application thereof, and belongs to the technical field of cherry gene engineering. A novel sugar transporter gene CpSWEET10 is obtained through cloning, the nucleotide sequence of the novel sugar transporter gene CpSWEET10 is shown as SEQ ID NO.1, and the coded amino acid sequence of the novel sugar transporter gene CpSWEET10 is shown as SEQ ID NO.2. The gene is highly expressed in cherry fruits, and the content of soluble solids and total sugar in mature fruits is remarkably positively correlated with the expression quantity of the soluble solids and the total sugar; through subcellular localization and sugar transport function defect type yeast mutant functional complementation experimental analysis, the protein coded by the CpSWEET10 gene is localized in a cytoplasmic membrane and has a sucrose transport function; the cherry sugar transporter gene CpSWEET10 disclosed by the invention can be applied to the improvement of the sugar degree character of the fruits, and a new gene resource is provided for molecular breeding for improving the high-sugar quality of the cherry fruits.

The invention provides an application of a peach transport protein PpSWEET11 in regulating and controlling the hexose content of fruits. According to the invention, the function of the PpSWEET11 gene is cloned and verified, and through overexpression of the PpSWEET11 in peach fruits and tomatoes, the glucose and fructose levels in an overexpression group are obviously increased compared with those in a control group, which indicates that the PpSWEET11 has a wide sugar transport function. The invention not only expounds the effect of the PpSWEET11 in the aspect of sugar accumulation and provides a key molecular insight in the aspect of improving sugar accumulation of peaches and other economically important fruit crops, but also can be applied to nutritional quality improvement and germplasm innovation of peach fruits.

The invention belongs to the technical field of genetic engineering, and relates to the field of wheat genetic engineering, in particular to a gene TaABCG42 for regulating and controlling cadmium accumulation of wheat as well as an encoding protein and application of the gene TaABCG42. According to the invention, a TaABCG42 gene is knocked out by using CRISPR / Cas9, a TaABCG42 gene overexpression plant is constructed at the same time, and a homozygous mutant is obtained by using a Hi-Tom sequencing technology and PCR (Polymerase Chain Reaction) successive generation screening. A wild type TaABCG42 homozygous overexpression and knockout plant treated with a 40 [mu] mol / L Cd solution for 5 days is subjected to analysis such as metal content determination, subcellular component metal determination, Cd chemical form determination and Cd ion flow determination, and the Cd absorption and transport approach of TaABCG42 is analyzed, so that the physiological and molecular mechanism of the TaABCG42 metal transporter for absorbing and transporting Cd is explored, and the application prospect is wide. The understanding on the wheat ABC metal transporter is enriched, and a theoretical basis is provided for cultivating high-quality wheat with low Cd accumulation.

The invention belongs to the technical field of biological medicine, and relates to application of a clerodendranthus spicatus tea bag in regulating intestinal excretion and reducing uric acid. One of the purposes of the invention is to provide the application of the clerodendranthus spicatus teabag in regulating intestinal tracts to reduce uric acid According to a preferred embodiment, the clerodendranthus spicatus teabag regulates ATP binding cassette transporter G2 and inhibits uricase activity. The invention provides the application of the clerodendranthus spicatus teabag in regulating the intestinal microbial environment and reducing uric acid, and the clerodendranthus spicatus teabag has remarkable beneficial effects. The clerodendranthus spicatus teabag can effectively regulate the structure and the function of intestinal microflora, especially the enrichment amount of characteristic bacteria Muriaculum in the intestinal tract, further strengthens the probiotic activity of the intestinal flora, and is helpful for maintaining the steady state of uric acid in the body. The multi-way synergistic effect not only provides an innovative strategy for preventing and treating hyperuricemia and related metabolic diseases, but also avoids side effects possibly brought by traditional medicines, and shows good application prospects and clinical values.

Methods of treating age-related macular degeneration (AMD) may include the administration of amphipathic, ATP binding cassette transporter membrane agonists to reduce the amount of drusen in the subject in need thereof. These methods may be particularly useful for treatment of intermediate AMD.

The invention relates to the field of synthetic biology, metabolic engineering and fermentation engineering, and discloses a genetically engineered bacterium and application thereof in production of alpha-ketoglutaric acid.The genetically engineered bacterium comprises the steps that the genetically engineered strain with escherichia coli BW25113 or corynebacterium glutamicum ATCC13032 as a host is constructed; overexpression type isocitrate dehydrogenase genes are integrated through chromosomes, alpha-ketoglutarate dehydrogenase complex genes are knocked out, NADPH invertase is overexpressed through plasmids, and exogenous AKG transporter protein is introduced, so that metabolic flux directional regulation and control and product efflux enhancement are realized; meanwhile, a staged fermentation process is adopted and comprises dynamic gradient adjustment of inorganic phosphorus concentration and two-stage pH control. According to the method, the AKG yield of 78.2 g / L can be obtained under the 5L tank scale, the sugar acid conversion rate reaches 0.68, and the method has the advantages of being high in yield, low in byproduct and controllable in cost. The obtained AKG is suitable for a plurality of fields such as medical intermediates, functional foods and cell culture additives, and has wide industrial application prospects.

The invention discloses a genetically engineered bacterium and an application of the genetically engineered bacterium in production of farnesene. The genetically engineered bacterium takes saccharomyces cerevisiae as a chassis strain; an exogenous beta-farnesene synthase gene is integrated, an ERG9 gene is knocked out, a promoter of a truncated HMG1 gene is replaced with an ANB1 promoter, an exogenous transhydrogenase gene is integrated and driven by a glucose sensitive promoter, beta-farnesene synthase is mutated and fused with a transmembrane structural domain of ABC transporter protein PDR10, and then a chimeric expression unit is constructed. According to the present invention, the chassis bacteria are modified by at least one of the steps of overexpression of phosphatidylcholine synthetase, knockout of sterol ester synthetase and introduction of exogenous alkyl glycerol monooxygenase, and the obtained engineering bacteria are combined with the optimized fermentation process so as to significantly improve the farnesene synthesis efficiency and the production economy; therefore, the genetically engineered bacterium and the fermentation method provided by the invention have good application prospects.

This invention relates to a method for producing chondroitin with improved safety and extracellular secretion levels, belonging to the field of genetic engineering. Using the probiotic *Escherichia coli* Nissle 1917 as the host, this invention designs methods to increase chondroitin production by studying the chondroitin synthase KfoAC and the chondroitin-linking Kdo synthase. The relationship between chondroitin synthesis and secretion in *E. coli* was clarified, and the specificity of the chondroitin-linking Kdo was investigated, resulting in an extracellular chondroitin production of 0.32 g / L. Subsequently, the introduction of the protein KfoB from the chondroitin synthesis gene cluster increased the extracellular chondroitin production to 0.51 g / L. Further screening and optimization of the expression of transport proteins resulted in an extracellular chondroitin production of 0.73 g / L in shake flasks. Further optimization using a 7-L fermenter resulted in an extracellular chondroitin production of 5.9 g / L.

One aspect of the present invention relates to: a conjugate comprising a peptide of a novel sequence and glycyrrhizin; and a pharmaceutical composition for preventing or treating obesity, the composition comprising the conjugate. The conjugate and composition comprising same according to one aspect were found to inhibit hypertrophy of fat cells, increase the cell membrane expression level of ATP-binding cassette transporter A1 (ABCA1), and reduce the secretion of tumor necrosis factor-α (TNF-α). In addition, the conjugate and composition comprising same were found to remain in a greater amount in the blood and have better pharmacokinetic properties than glycyrrhizin used by itself, and thus can be used in the obesity prevention and / or treatment market / industry.

The invention discloses a method for constructing a high-yield natamycin engineering strain through overexpression of an extracellular transport protein gene pimA and a pathway specific regulation gene pimR, and the high-yield engineering strain is applied to fermentation production of natamycin. The yield of the natamycin can reach 19.49 g / L through fed-batch fermentation in a fermentation tank of 5L of the high-yield strain S.ilvosporeus pimA-pimR, and the yield of the natamycin is improved by 33.12% compared with the yield of a chassis strain S.ilvosporeus TUST01; the production intensity is improved by 33.33% compared with the production intensity of a chassis strain S.ilvosporeus TUST01, and the strain has a relatively high industrial application value.

The application discloses a method for promoting transport and improving retinal synthesis, which is obtained by introducing an exogenous ABC transport protein Pdr5 into a host fungus and adding a copy of beta-carotene-15, 15'-monooxygenase BLH; wherein the host fungus is a genetically modified Pichia pastoris strain PP-BCCIV. The application further verifies the retinal production performance of the recombinant strain by screening different surfactants, and further improves the ability of Pichia pastoris to produce retinal. At the same time, all the retinal is extracted into the extracellular, and all the carotenes are left in the intracellular, so as to achieve the co-production of carotenes and retinal. The recombinant Pichia pastoris of the application has a simple construction method, can better promote the synthesis of retinal and other vitamin A, and can make the engineering strain utilize glucose and methanol to efficiently synthesize retinal through a 5 L fermentation tank, which is beneficial to industrial production.

Provided are a recombinant Escherichia coli with improved ability to secrete extracellular endoglucanase (BcsZ) and a construction method therefor. The recombinant Escherichia coli is constructed by using Escherichia coli JBZ-DH5α as a starting strain and inserting a membrane protein coding gene. The membrane protein gene is one of the following coding genes: a coding gene of zinc transporter permease znuB, a coding gene of DUF1449 family inner membrane protein ylaC, and a coding gene of UPF0410 family inner membrane protein ymgE.

The invention relates to the technical field of preparation of deep-sea longevity fish precise active peptides, in particular to a deep-sea longevity fish precise active peptide with uric acid reducing and anti-inflammatory effects as well as a preparation method and application of the deep-sea longevity fish precise active peptide. The preparation method comprises the following steps: carrying out medium-temperature pretreatment, carrying out step-by-step enzymolysis with alkaline protease and acid protease, centrifuging, filtering, carrying out ultrafiltration interception and the like, and screening out 10 non-reported non-toxic active peptide fragments. The active peptide has a multi-target synergistic effect, inhibits the activity of xanthine oxidase, regulates and controls the expression of uric acid resorption protein, regulates and controls the expression of uric acid transporter protein, realizes bidirectional regulation of uric acid metabolism, efficiently removes hydroxyl radicals, activates superoxide dismutase and reduces the content of inflammation-related factors. The technology is simple and easy to control, low in equipment requirement and suitable for large-scale production, the active ingredients are natural, safety is high, the active ingredients can serve as functional factors to be applied to functional food, health care products and the like, and safe and diversified intervention schemes are provided for hyperuricemia and related inflammation problems.

The invention relates to the technical field of gene engineering, and discloses a recombinant strain, a construction method and application thereof, and a method for producing total fatty acid. The recombinant strain is obtained by genetic modification of an original strain, and compared with the original strain, the recombinant strain overexpresses citric acid transporter Yhm2p, cis-aconitase E.HA and isocitrate dehydrogenase IDP located in cytoplasm at the same time, and does not express isocitrate dehydrogenase IDH1 and isocitrate dehydrogenase IDH2 located in mitochondria. The recombinant strain provided by the invention forms a high-efficiency pathway of citric acid retention-cytoplasm transport-directional production of NADPH, so that the core bottleneck of insufficient supply of cytoplasm NADPH in fatty acid synthesis is solved, the total fatty acid yield is remarkably increased, the transformation logic is accurate, and a stable and reliable source is provided for industrial high-efficiency production of fatty acid.

The invention relates to the technical field of polypeptide compositions, and discloses a silkworm-derived protein peptide with blood sugar regulation and immune function activity and an application method, the silkworm-derived protein peptide comprises a silkworm-derived acidic active peptide group, a silkworm-derived alkaline daemon peptide group, a divalent cation coordination center and a silkworm-derived proline enriched peptide group; the silkworm source acidic active peptide group and the silkworm source alkaline daemon peptide group are mixed according to the mass ratio of (3: 1)-(5: 1), and an electrically neutral nano peptide cluster with the average particle size smaller than 100 nm is formed through electrostatic complexation; the silkworm-derived alkaline daemon peptide group contains histidine residues, imidazolyl of the silkworm-derived alkaline daemon peptide group is protonated in an acid environment to generate charge repulsive force, electrostatic repulsive force generated when active peptide penetrates through intestinal epithelial cell membranes is eliminated by utilizing a component charge counteracting mechanism, the apparent treatment flux of transporter protein on core components is enhanced, and the biological activity of the silkworm-derived alkaline daemon peptide group is improved. And intracellular dissociation of the peptide cluster is triggered by virtue of a protonation induction lock, so that accurate resetting of an active site at a target spot is ensured, and the technical problems that transmembrane absorption of the high-activity polar peptide is limited and intracellular release is delayed are solved.

The invention discloses a genetically engineered bacterium for synthesizing L-glutamine by taking glucose as a carbon source and application of the genetically engineered bacterium. The genetically engineered bacterium takes escherichia coli as a chassis strain; according to the invention, a citrate synthase gene gltA, an aconitic acid hydratase gene can, an isocitrate dehydrogenase gene icd, a glutamate dehydrogenase gene gdh, a glutamine synthetase gene glnA and ammonium transporter genes amt and amtb can be overexpressed. Compared with the prior art, the invention provides a new strain and a new method for biosynthesizing L-glutamine, and the new strain and the new method have the significances of economy, scientificity, low cost, simple process and large-scale production.

The present invention relates to a novel PTS transporter subunit EIIC variant and a method of producing 5′-inosinic acid using the same. The PTS transporter subunit EIIC variant is obtained by substituting one or more amino acids in the amino acid sequence constituting PTS transporter subunit EIIC to change the activity of the protein, and a recombinant microorganism comprising the PTS transporter subunit EIIC variant is capable of efficiently producing 5′-inosinic acid.

This invention relates to the field of biosynthesis technology, and particularly to engineered yeast strains and their application in the total fermentation production of steviol glycosides. This invention utilizes site-directed mutagenesis to mutate wild-type kaurenoic acid 13-hydroxylase, obtaining the G481L / Q159L mutant. This mutant is then applied to the production of steviol or steviol glycosides, constructing a steviol or steviol glycoside synthesis pathway in the *Saccharomyces cerevisiae* host to achieve efficient production of steviol or steviol glycosides. Simultaneously, by enhancing the level of diterpene precursor synthesis genes in chassis cells (MVA pathway, acetyl-CoA, GGPP, transport proteins, UDPG pathway), the yield of steviol glycosides is further increased, reducing costs for industrial production.

The invention discloses an ingenol ABC transport protein ElABCG39 as well as a coding gene and application thereof. The protein is positioned in a cytoplasmic membrane, and expression of the protein in yeast proves that the protein has ingenol transmembrane efflux transport function, improves the ingenol tolerance of the yeast, and proves that the ElABCG39 has certain substrate specificity in the yeast. The ingenol ABC transporter ElABCG39 can be used for producing ingenol by fermentation of microorganisms or plant tissues.

Provided herein are kits, compositions, systems, and methods for treating a subject with a tumor with kynurenine responsive and degrading bacteria (e.g., such that the bacteria reduces or eliminates the tumor). In certain embodiments, the kynurenine responsive bacteria comprise one or more nucleic acid sequences encoding: i) a kynurenine transcriptional regulator protein, ii) a kynurenine transporter protein, iii) a kynureninase (KynU) protein, and iv) at least one protein important or essential for growth of the bacteria expression of which is linked to a kynurenine responsive promoter (e.g., where the corresponding gene(s) has been deactivated or knocked out in the genome of the bacteria).

Described herein are methods for disease or disorder associated with GABA transporter 1 (GAT-1) dysfunction. In one aspect described herein, the disease or disorder is associated with one or more solute carrier Family 6 Member 1 (SLC6A1) mutations, and 4-phenylbutyrate, or the pharmaceutically acceptable salt thereof, is administered at a dose of 75 mg / kg / day to 125 mg / kg / day. In another embodiment, the method comprises combined GAT-1 gene therapy combined with administration of 4-phenylbutyrate.

The application provides a genetically engineered bacterium for producing lactose-N-neotetraose, a construction method and application thereof. The genetically engineered bacterium satisfies the following conditions: (1) exogenous expression of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase; (2) overexpression of galactoside permease and UDP-galactose-4-epimerase; and (3) no expression or weakened expression of setA transporter protein. The applicant of the application finds through research that exogenous introduction of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase in the genetically engineered bacterium, enhancement of the expression amount of galactoside permease and UDP-galactose-4-epimerase in the genome, and reduction of the expression amount of setA transporter protein can effectively reduce the residual amount of LNT II in the LNnT synthesis pathway and improve the fermentation yield of LNnT.

Presented herein are plants with altered photorespiratory characteristics. Disruption of transport proteins involved in shuttling glycolate and / or glycerate results in reductions in photosynthetic rates, reduced plant growth and alterations in gene expression and photosynthetic metabolite profiles. Such disruptions are also combined with introduced genes expressing components of alternate photorespiratory enzyme pathways to increase photosynthetic efficiency.

The present application discloses a recombinant microorganism for producing ergothioneine, a recombinant expression vector and a method for preparing ergothioneine. The recombinant microorganism carries a gene encoding ergothioneine synthase and expresses ATP-binding cassette transporter protein C1. The inventors found that using the transporter protein ABCC1, ergothioneine can be efficiently synthesized in microorganisms such as Escherichia coli, which has important application prospects.

The application discloses a ubiquitin transporter AcRAD23D1, a coding gene and application thereof, and belongs to the technical field of genetic engineering. The application clones an AcRAD23 family gene AcRAD23D1 from a kiwi fruit, and compares phenotypes and determines physiological parameters under transgenic and drought stress treatment, and identifies biological functions of the gene in positive regulation of drought resistance of the kiwi fruit in detail. The research result has important theoretical significance and practical application value for carrying out molecular directional breeding of the kiwi fruit. The overexpression transgenic kiwi fruit plant obtained by using the agrobacterium-mediated maceration method has significantly increased drought stress resistance, the transgenic kiwi fruit plant with silenced expression has significantly reduced drought stress resistance, and the application has important application value in molecular directional breeding of the kiwi fruit and reduction of cultivation environment limitation.

Provided herein are genetically modified yeast cells capable of producing one or more human milk oligosaccharides (HMOs) and methods of making such cells. The yeast cells are engineered to comprise a heterologous nucleic acid encoding a transporter protein and one or more heterologous nucleic acids that encode enzymes of a HMO biosynthetic pathway. Also provided are fermentation compositions including the disclosed genetically modified yeast cells, and related methods of producing and recovering HMOs generated by the yeast cells.

The present invention provides isolated DNA molecule(s), isolated polypeptide(s), artificial vector(s), and cell(s) including same. Further provided are methods for increasing the amount of an amino acid, as well as for synthesizing L-DOPA including a derivative thereof.

The present disclosure relates to a genetically modified cell capable of utilizing sucrose as energy and carbon source following the expression of a single heterologous enzyme, which upon expression is translocated from the cytosol and which is capable of hydrolysing non-phosphorylated sucrose into fructose and glucose.The identification of efficient enzymes capable of hydrolysing sucrose in its non-modified form, and which on its own enable the cell to utilize sucrose as a, or as the main and / or sole, carbon and / or energy source, i.e., without the need for multi-gene sucrose utilizing systems comprising several other heterologous polypeptides, such as other enzymes and / or transporters, is highly advantageous, since it allows for cost-effective use of sucrose in large scale production processes.